Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poa pratensis pollen allergen extract, glutaraldehyde-modified is a therapeutic allergoid vaccine developed by Inmunotek for allergen immunotherapy (AIT). It consists of Kentucky Blue Grass (*Poa pratensis*) pollen proteins that have been chemically polymerized with glutaraldehyde. This modification reduces the number of IgE-binding epitopes, thereby decreasing the risk of immediate allergic reactions (anaphylaxis) during administration, while preserving the T-cell epitopes necessary for inducing immunological tolerance. The extract is typically adsorbed onto aluminum hydroxide to provide a depot effect, allowing for a sustained release and a 'cluster' up-dosing schedule. It is indicated for patients with IgE-mediated allergic rhinitis, rhinoconjunctivitis, and mild-to-moderate allergic asthma who have not responded adequately to symptomatic treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poa pratensis pollen allergen extract, glutaraldehyde-modified.